Published Date: 02 Mar 2023
Although it is recognized that pain is common among nursing home residents, little attention has been paid to how this pain changes over time. A new study from the Regenstrief Institute and the Indiana University School of Nursing...
Read Full NewsKYV-101 shows promising efficacy in treating generalized myasthenia gravis, offering hope for durable remission through innovative CAR T-cell therapy.
Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.
MIL62 Shows Increased Remission and Reduced Relapse Versus Cyclosporine A in MN
AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies
Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day
The HCPFive: Top News for Healthcare Providers from the Week of 11/16
1.
AI Model Has Promise for Predicting Checkpoint Inhibitor Activity in NSCLC
2.
Addition of regional nodal irradiation does not decrease rates of invasive breast cancer recurrence, study finds
3.
What does it mean for Biden's prostate cancer to be 'aggressive'? A urologic surgeon explains
4.
AI could help improve early detection of interval breast cancers
5.
June 20, 2023, Health Bulletin No. 12.
1.
Unravelling the Mysteries of Monoclonal Gammopathy
2.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
3.
Unveiling the Invisible: The Transformative Role of Radiomics in Precision Oncology
4.
What You Need to Know About the Early Warning Signs of Colon Cancer
5.
MMA Embolization in Chronic Subdural Hematoma: Evidence, Outcomes, and Gaps
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
5.
Navigating the Complexities of Ph Negative ALL - Part XII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation